Large cohort study links allergic rhinitis to higher risk of vision-threatening optic neuritis

Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic ...
Medscape

Allergic Diseases Tied to Increased Risk for Optic Neuritis

Individuals with allergic diseases, particularly allergic rhinitis, have a higher risk of developing optic neuritis than ...
Healio

Analysis identifies predictors of poorer acute optic neuritis outcomes

Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.
JSTOR Daily

Disease Of The Anterior Ethmoid Cells As A Cause Of Optic And Retrobulbar Neuritis

Vision – To be the world's leading and most trusted provider of information and services that will make a real difference in clinical practice and improve outcomes for patients. Mission – To lead the ...
Hosted on MSN

Oculis’ acute optic neuritis therapy trial meets primary endpoint

Oculis Holding has reported that the randomised Phase II Acute OptiC NeUrITis of DemYelinating Origin (ACUITY) trial of OCS-05, in treating individuals with acute optic neuritis, met the primary ...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic ...
Nasdaq

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...
Ophthalmology Times

Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION

Privosegtor (also known as OCS-05) is a “first-in-class peptoid small molecule” for neuroprotective therapy for acute optic ...